Breadcrumb Navigation

PSMA PET (prostate cancer)

PSMA-PET with 18F-PSMA approved in Switzerland since October 2019. Compared to choline PET, PSMA PET has a significantly higher sensitivity for lymph node and distant metastases and, in contrast to choline PET, can also be used well for initial staging in prostate cancer.

Coronary MIP uptake in this 67-year-old patient provides a first overall view. After a radical prostate resection in 2013, the PSA increased again to currently 0.22 ng/ml. Axial fused images demonstrate focal PSMA enhancement in a pararectal lymph node as small as 3 mm in diameter (yellow arrow). This is therefore, despite the small size suspicious for a lymph node metastasis.
Coronary MIP uptake in this 67-year-old patient provides a first overall view. After a radical prostate resection in 2013, the PSA increased again to currently 0.22 ng/ml. Axial fused images demonstrate focal PSMA enhancement in a pararectal lymph node as small as 3 mm in diameter (yellow arrow). This is therefore, despite the small size suspicious for a lymph node metastasis.

Indications

The following indication is reimbursed by the health insurance:

  • Biochemically proven recurrence (PSA increase) of a prostate carcinoma.
  • The primary staging is also reimbursed by the health insurance for high-risk prostate carcinoma and intermediate-risk prostate carcinoma.
Details see PDF, page 105ff

Responsible doctors

Martin Hüllner, PD Dr. med.

Senior Attending Physician, Department of Nuclear Medicine
Deputy Clinic Director, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Diagnostic Neuroradiologist, Department of Nuclear Medicine

Specialties: Oncological, neurological and musculoskeletal imaging
Tel. +41 44 255 25 80

Lars Husmann, Prof. Dr. med.

Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine

Specialties: PET/CT Imaging
Tel. +41 43 253 87 99

David Kenkel, PD Dr. med.

Attending Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine

Specialties: Oncological imaging (PET, SPECT, CT, MRI)

Cäcilia Mader, Dr. med.

Senior Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine
Neuroradiologist, Department of Nuclear Medicine

Specialties: Oncological, neurological and musculoskeletal hybrid imaging
Tel. +41 43 253 88 02

Alexander Maurer, Dr. med.

Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine

Specialties: Oncologic imaging, Hybrid imaging of prostate cancer
Tel. +41 43 253 88 09

Michael Messerli, PD Dr. med.

Attending Physician, Department of Nuclear Medicine
Nuclear Medicine Physician, Department of Nuclear Medicine
Radiologist, Department of Nuclear Medicine

Specialties: Hybrid imaging of oncological diseases (PET, SPECT, CT, MRI)
Tel. +41 43 253 88 03

For patients

As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.

Tel. +41 44 255 35 55

For referring physicians

Simply assign your patient via registration form.

Tel. +41 44 255 35 55

Medical information hotline: 08.00-18.00 o’clock: +41 44 255 15 02